In general, CD4+ Th1, infiltrating CD8+ CTLs and CD103+ cDC1s contribute to the main anti-tumor effects observed upon the induction of various immunomodulatory treatment regimens, including checkpoint inhibitors, oncolytic viruses, radiotherapy, chemotherapy, or adoptive T-cell therapy [32]. This evidence concerns the gene CD8A and neoplasm.